Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ATG-022 compared to Investigators Choice treatment in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who have received prior second-line systemic therapy. This Phase III, randomized, controlled, open-label study involves participants with unresectable locally advanced or metastatic disease who have progressed after at least second-line and no more than fourth-line systemic therapy. The study is based on positive earlier data and aims to compare ATG-022 monotherapy with commonly used chemotherapy options. Participants receive either ATG-022 monotherapy at a dose of 1.8 mgkg every 21 days one cycle or Investigators Choice chemotherapy, which includes either Docetaxel or Irinotecan. Docetaxel is administered at 75-100 mgm every 21 days, while Irinotecan is given at 125 mgm on days 1 and 8 every 21 days. The study uses a parallel design to compare these two treatment regimens. Throughout the trial, participants undergo tumor assessments at baseline and then every 6 weeks during treatment, followed by less frequent evaluations after 12 and 24 months until disease progression or death. Survival follow-up occurs every 3 months until death or study end. Researchers measure progression-free survival, overall survival, objective response rate, disease control rate, and duration of response. Laboratory tests and physical examinations are conducted to monitor organ function and safety. Participants remain in the study until disease progression, death, or study completion, with ongoing monitoring of their health.
Actively Recruiting
Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.
Actively Recruiting
Researchers are evaluating the drug brenipatide compared to a placebo to see if it works and is safe for adults with Alcohol Use Disorder AUD and hazardous alcohol use. This phase 3 study aims to understand how brenipatide affects drinking patterns over time. Participation in this trial will last about 56 weeks, with careful monitoring throughout. Participants will receive brenipatide or placebo through subcutaneous injections. The study includes escalating doses of brenipatide administered under the skin. Participants must self-inject the study drug or receive assistance from a trained support person if needed. The treatment phase is structured in parallel groups, comparing the drug against placebo. During the study, participants will attend regular visits and be asked to maintain study diaries and complete questionnaires. Researchers will assess changes in drinking patterns using the Timeline Followback Method, daily alcohol consumption, alcohol cravings, and health outcomes such as body weight and quality of life. Blood samples will be collected to measure brenipatide levels and monitor for any immune responses. The study includes safety monitoring and lasts for approximately 56 weeks.
Actively Recruiting
Phase 3 Randomized Trial Evaluating MI078 Capsules in Women with Postpartum Depression Aged 18 to 45
The trial investigates the use of MI078 capsules to treat postpartum depression in women aged 18 to 45 years. It is a multicenter, randomized, double-blind, placebo-controlled study aiming to assess the efficacy and safety of MI078 for this condition. Participants must have a diagnosis of major depressive disorder with onset during late pregnancy or early postpartum, and a certain level of depression severity as measured by the Hamilton Depression Rating Scale. Participants are randomly assigned to two groups one receiving MI078 capsules and the other receiving a matching placebo. The treatment is taken for 3 days during the treatment period. The study includes a screening phase lasting up to 14 days before treatment, a 4-day treatment period, and a follow-up period lasting until day 31 after treatment begins. During the study, participants will undergo clinical assessments including depression rating scales such as the HAM-D17 and other mood and anxiety scales. Researchers will monitor changes from baseline in depression scores and record safety information throughout the follow-up period. Participants are expected to comply with study requirements, lifestyle restrictions, and attend scheduled visits for evaluations over approximately one month.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elecoglipron compared with a placebo to help manage weight in adults living with obesity or overweight, including those with or without type 2 diabetes mellitus. This Phase III, randomized, double-blind, placebo-controlled study involves multiple centers and aims to assess elecogliprons impact on weight management over time. Participants will be randomly assigned to receive either one of two doses of elecoglipron or a matching placebo tablet taken once daily, alongside diet and exercise. The study will last for 52 weeks, during which efficacy and safety will be continuously evaluated. The study includes adults with a body mass index BMI of 28 kgm or higher, or those with a BMI between 24 and less than 28 kgm with at least one weight-related health issue. During the study, participants will undergo regular assessments including body weight measurements and waist circumference at baseline and at Week 52. Researchers will monitor changes in body weight, specifically the percent change from the start to Week 52, and the number of participants achieving at least 5% and 10% weight loss. Safety evaluations will be conducted throughout the trial to ensure participant well-being.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
1-10 of 18
1